Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib vs Sorafenib in MET+ Advanced HCC
NCT01988493Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of tepotinib in hepatocellular carcinoma (HCC) (5 arms), sponsored by Merck KGaA. Primary endpoints: Dose Limiting Toxicity, Treatment Emergent Adverse Events up to 94 weeks and 1 more. Started Jan 2014; status: completed.
02
Drugs
tepotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01988493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01988493.